Treatment for Stage 4 Retrovirus Disease (AIDS)
Start antiretroviral therapy (ART) immediately upon diagnosis with an integrase strand transfer inhibitor (InSTI)-based regimen, specifically bictegravir or dolutegravir combined with tenofovir (TDF or TAF) plus emtricitabine or lamivudine, initiating within 7 days of diagnosis or even same-day if no active opportunistic infection is suspected 1.
When to Initiate Treatment
ART should begin as soon as possible after diagnosis, ideally within 7 days, including same-day initiation at the first clinic visit if the patient is ready 1. The only exception is when there is suspicion for a concomitant opportunistic infection, which requires specific timing considerations detailed below.
Recommended First-Line Regimens
The preferred initial regimens for stage 4 HIV disease (AIDS) are 1, 2:
Triple therapy options:
- Bictegravir/tenofovir alafenamide/emtricitabine (BIC/TAF/FTC)
- Dolutegravir + tenofovir (TDF or TAF) + lamivudine or emtricitabine (DTG + TDF/TAF + 3TC/FTC)
- Doravirine + tenofovir + lamivudine/emtricitabine (DOR + TDF/TAF + 3TC/FTC)
Dual therapy option:
- Dolutegravir + lamivudine or emtricitabine (DTG + 3TC/FTC)
Why InSTI-Based Regimens?
These regimens are recommended due to 1:
- High viral suppression rates
- Excellent tolerability with infrequent toxicity
- Limited drug-drug interactions
- High barrier to resistance development
- Low pill burden (often single-tablet regimens)
Critical Timing Considerations with Opportunistic Infections
Active Tuberculosis (TB)
- Without TB meningitis: Start ART within 2 weeks after initiating TB treatment, especially if CD4+ count is below 50 cells/μL 1
- With TB meningitis: Start high-dose corticosteroids and TB treatment immediately; delay ART initiation until TB meningitis is controlled (clinical improvement and normalizing CSF parameters), typically 2-4 weeks after starting TB treatment 1
Cryptococcal Meningitis
- Start ART 2-4 weeks after beginning antifungal therapy 1
- Earlier initiation (2 weeks): For patients who have clinically improved, have controlled intracranial pressure, have negative CSF cultures on antifungal therapy, and can be closely monitored
- Later initiation (4 weeks): For those who do not meet the above criteria
Other Opportunistic Infections
- Generally initiate ART within 2 weeks of starting treatment for most opportunistic infections 1
Important Caveats for Advanced Disease
While integrase inhibitors are the preferred agents, there has been concern about potentially higher rates of immune reconstitution inflammatory syndrome (IRIS) with these potent agents in advanced disease 3. However, the 2025 IAS-USA guidelines do not modify the recommendation for InSTI-based regimens even in stage 4 disease, as the benefits of rapid viral suppression outweigh theoretical IRIS concerns when patients are appropriately monitored 1.
The key is close monitoring for IRIS, particularly in the first 2-4 weeks after ART initiation in patients with CD4+ counts below 50 cells/μL or active opportunistic infections.
Addressing Barriers to Treatment
Structural barriers that could delay ART receipt or impede adherence must be addressed using evidence-informed strategies 1. This is particularly critical in stage 4 disease where delays in treatment initiation directly impact mortality.
Monitoring and Expected Outcomes
With current InSTI-based regimens, the majority of patients achieve durable viral suppression below detectable levels 4. Life expectancy for patients with HIV who consistently take ART now approaches that of the general population 4, even when starting at advanced stages, though outcomes are better with earlier initiation.